Literature DB >> 14582335

[Therapeutic efficacy of 3 treatment protocols for non-complicated Plasmodium falciparum malaria, Antioquia, Colombia, 2002].

Silvia Blair1, Mary Luz López, Juan Gabriel Piñeros, Tania Alvarez, Alberto Tobón, Jaime Carmona.   

Abstract

High resistance of Plasmodium falciparum malaria to chloroquine poses malaria as a major public health problem in Colombia. In this context, the therapeutic response of uncomplicated P. falciparum malaria patients to chloroquine (CQ), sulfadoxine/pirymethamine (SDXP) and combined therapy (SDXP/CQ) was evaluated according to the WHO/PAHO protocols of 1998. The comparisons were based on a sample of 160 patients with uncomplicated P. falciparum malaria in Turbo and Zaragoza (Antioquia, Colombia). Patients were randomly assigned each of the treatment categories. The results were statistically similar in each municipality. In Turbo percentage of treatment failure was 87.5%, 22.2% and 22.6% for CQ, SDXP and SDXP/CQ, respectively, whereas in Zaragoza, the corresponding treatment failure was 77.7%, 26.5% and 12.1%. During follow up, 50% of subjects with late treatment failure were asymptomatic in Turbo, while 33.3% were asymptomatic in Zaragoza. A high level of treatment failure occurred with CQ monotherapy, while SDXP and SDXP/CQ had acceptable levels of failure, i.e., below 25%. The high percentage of late treatment failure in asymptomatic patients may contribute to increased risk of persistent transmission.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582335

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  2 in total

Review 1.  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.

Authors:  H M McIntosh; K L Jones
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

2.  Nosocomial Plasmodium falciparum infections confirmed by molecular typing in Medellín, Colombia.

Authors:  Lina González; Jesus Ochoa; Liliana Franco; Marta Arroyave; Eliana Restrepo; Silvia Blair; Amanda Maestre
Journal:  Malar J       Date:  2005-02-09       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.